$OCGN News

Ocugen to Participate in Upcoming July Industry Conferences

Ocugen: Financing Risk Is Lower, But The Clinical Bet Still Has To Work

Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View

How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance

Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Canaccord Genuity Maintains Buy on Ocugen, Lowers Price Target to $11

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

Ocugen (OCGN) Reports Q1 EPS

Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed?

Ocugen (OCGN) Upgraded to Buy: Here's Why

Ocugen Q1 Earnings Call Highlights

Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript

Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Full Transcript: Ocugen Q1 2026 Earnings Call

Ocugen Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $1.533M Beat $540.000K Estimate

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes